QIAGEN Lowers 2026 Sales Growth Forecast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy QGEN?
Source: stocktwits
- Sales Forecast Cut: QIAGEN has revised its 2026 net sales growth forecast down from at least 5% to 1-2%, primarily due to sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty, indicating signs of weak market demand.
- Q2 Outlook: The company anticipates a decline of approximately 2% in net sales for the second quarter from last year's $534 million, with adjusted EPS expected to remain at least $0.60, reflecting a cautious outlook on future performance.
- Preliminary Q1 Data: QIAGEN reported preliminary Q1 net sales of $492 million, up 2% on a reported basis but down 1% at constant exchange rates, falling short of its prior outlook for at least 1% growth, highlighting weak QuantiFERON sales.
- Market Reaction: Retail sentiment around QIAGEN shifted from 'bullish' to 'neutral', with the stock falling 15% over the past 12 months, reflecting investor concerns about the company's future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QGEN
Wall Street analysts forecast QGEN stock price to rise
14 Analyst Rating
8 Buy
6 Hold
0 Sell
Moderate Buy
Current: 38.410
Low
45.00
Averages
50.57
High
55.00
Current: 38.410
Low
45.00
Averages
50.57
High
55.00
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QIAGEN Lowers 2026 Sales Growth Forecast
- Sales Forecast Cut: QIAGEN has revised its 2026 net sales growth forecast down from at least 5% to 1-2%, primarily due to sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty, indicating signs of weak market demand.
- Q2 Outlook: The company anticipates a decline of approximately 2% in net sales for the second quarter from last year's $534 million, with adjusted EPS expected to remain at least $0.60, reflecting a cautious outlook on future performance.
- Preliminary Q1 Data: QIAGEN reported preliminary Q1 net sales of $492 million, up 2% on a reported basis but down 1% at constant exchange rates, falling short of its prior outlook for at least 1% growth, highlighting weak QuantiFERON sales.
- Market Reaction: Retail sentiment around QIAGEN shifted from 'bullish' to 'neutral', with the stock falling 15% over the past 12 months, reflecting investor concerns about the company's future growth prospects.
See More
QIAGEN Lowers 2026 Sales Growth Outlook Amid Q1 Results
- Q1 Sales Performance: QIAGEN N.V. reported preliminary Q1 2026 sales of $492 million, falling short of the analyst estimate of $501.49 million, indicating potential market demand weakness that could impact short-term financial performance.
- Earnings Guidance Adjustment: Adjusted diluted EPS came in at $0.54, aligning with analyst expectations, but the full-year EPS guidance was lowered from $2.50 to at least $2.43, reflecting a cautious outlook on future profitability.
- Sales Growth Outlook Downgrade: The company revised its FY2026 sales growth outlook down from at least 5% to approximately 1-2%, indicating greater market challenges that may affect QIAGEN's long-term strategic planning.
- Future Outlook: Although Q2 2026 sales are expected to decline by about 2%, management anticipates stronger performance in the second half of 2026 driven by new product launches and easing market headwinds, demonstrating confidence in future growth.
See More
QIAGEN Files Annual Report for 2025
- Annual Report Submission: QIAGEN N.V. has filed its annual report and audited consolidated financial statements for the fiscal year ending December 31, 2025, with the U.S. Securities and Exchange Commission, demonstrating the company's ongoing commitment to transparency and compliance.
- Free Report Availability: The company will provide printed copies of the 2025 Annual Report to shareholders upon request, reflecting its emphasis on shareholder communication and service.
- Global Customer Base: QIAGEN serves over 500,000 customers in the life sciences and molecular diagnostics sectors, showcasing its extensive influence and leadership position in the global market.
- Employee Scale and Distribution: As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations worldwide, indicating its continued efforts in global business expansion and talent management.
See More
New Study Supports QuantiFERON-TB Gold Plus Use in High-Risk Populations
- Enhanced Detection Efficacy: A new study indicates that QuantiFERON-TB Gold Plus testing reduces the modeled lifetime risk of progression to active TB by 41% among HIV-infected individuals in Thailand compared to traditional skin testing, significantly improving detection accuracy and cost-effectiveness.
- Global Event Promotion: QIAGEN will host the global QuantiFERON World TB Day event on March 24, 2026, bringing together international experts to discuss advancements in TB detection and prevention, aiming to elevate global awareness and response to tuberculosis.
- Investment in Technological Innovation: QIAGEN is developing a fifth generation of QuantiFERON tests and exploring the use of artificial intelligence to identify individuals at risk of latent TB infection, thereby enhancing early risk prediction capabilities to support more targeted preventive treatment.
- Response to Market Demand: With approximately 10 million people developing active TB each year globally, QIAGEN is committed to meeting the increasing demand for TB testing by enhancing laboratory workflows and automation solutions, further solidifying its market leadership.
See More
Key Wall Street Ratings Updates on Friday
- Nvidia Price Target Raised: Daiwa increased Nvidia's price target from $205 to $215, anticipating that CEO Jensen Huang will showcase multiple AI success stories at the upcoming GTC Conference, which could positively impact the company's future performance.
- Qiagen Upgrade to Buy: Deutsche Bank upgraded Qiagen from hold to buy, noting that despite a nearly 30% drop in shares since January, the current price reflects the removal of any acquisition premium, suggesting potential for future price recovery.
- Nio Earnings Visibility: HSBC upgraded Nio from hold to buy, highlighting that new models and growth in its core portfolio may support volume growth and margin expansion, thereby enhancing its competitive position in the EV market.
- Linde Pricing Power: JPMorgan upgraded Linde from neutral to overweight, asserting that the chemical company possesses strong pricing power under current market conditions, which could help it maintain a competitive edge in the industry.
See More
Wall Street Analysts Adjust NIO Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on NIO stock, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Overview of Rating Updates: The adjustments include upgrades, downgrades, and initiations, indicating differing expectations from analysts regarding NIO's future performance, which may lead to stock price volatility.
- Market Reaction Potential: Changes in analyst ratings could attract investor attention, potentially impacting NIO's market performance, especially in the currently competitive electric vehicle sector.
- Investor Decision Impact: As analysts revise their views on NIO, investors may reassess their investment strategies, thereby affecting NIO's stock price trajectory and overall market confidence.
See More
QIAGEN Lowers 2026 Sales Growth Forecast
- Sales Forecast Cut: QIAGEN has revised its 2026 net sales growth forecast down from at least 5% to 1-2%, primarily due to sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty, indicating signs of weak market demand.
- Q2 Outlook: The company anticipates a decline of approximately 2% in net sales for the second quarter from last year's $534 million, with adjusted EPS expected to remain at least $0.60, reflecting a cautious outlook on future performance.
- Preliminary Q1 Data: QIAGEN reported preliminary Q1 net sales of $492 million, up 2% on a reported basis but down 1% at constant exchange rates, falling short of its prior outlook for at least 1% growth, highlighting weak QuantiFERON sales.
- Market Reaction: Retail sentiment around QIAGEN shifted from 'bullish' to 'neutral', with the stock falling 15% over the past 12 months, reflecting investor concerns about the company's future growth prospects.
See More
QIAGEN Lowers 2026 Sales Growth Outlook Amid Q1 Results
- Q1 Sales Performance: QIAGEN N.V. reported preliminary Q1 2026 sales of $492 million, falling short of the analyst estimate of $501.49 million, indicating potential market demand weakness that could impact short-term financial performance.
- Earnings Guidance Adjustment: Adjusted diluted EPS came in at $0.54, aligning with analyst expectations, but the full-year EPS guidance was lowered from $2.50 to at least $2.43, reflecting a cautious outlook on future profitability.
- Sales Growth Outlook Downgrade: The company revised its FY2026 sales growth outlook down from at least 5% to approximately 1-2%, indicating greater market challenges that may affect QIAGEN's long-term strategic planning.
- Future Outlook: Although Q2 2026 sales are expected to decline by about 2%, management anticipates stronger performance in the second half of 2026 driven by new product launches and easing market headwinds, demonstrating confidence in future growth.
See More
QIAGEN Files Annual Report for 2025
- Annual Report Submission: QIAGEN N.V. has filed its annual report and audited consolidated financial statements for the fiscal year ending December 31, 2025, with the U.S. Securities and Exchange Commission, demonstrating the company's ongoing commitment to transparency and compliance.
- Free Report Availability: The company will provide printed copies of the 2025 Annual Report to shareholders upon request, reflecting its emphasis on shareholder communication and service.
- Global Customer Base: QIAGEN serves over 500,000 customers in the life sciences and molecular diagnostics sectors, showcasing its extensive influence and leadership position in the global market.
- Employee Scale and Distribution: As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations worldwide, indicating its continued efforts in global business expansion and talent management.
See More
New Study Supports QuantiFERON-TB Gold Plus Use in High-Risk Populations
- Enhanced Detection Efficacy: A new study indicates that QuantiFERON-TB Gold Plus testing reduces the modeled lifetime risk of progression to active TB by 41% among HIV-infected individuals in Thailand compared to traditional skin testing, significantly improving detection accuracy and cost-effectiveness.
- Global Event Promotion: QIAGEN will host the global QuantiFERON World TB Day event on March 24, 2026, bringing together international experts to discuss advancements in TB detection and prevention, aiming to elevate global awareness and response to tuberculosis.
- Investment in Technological Innovation: QIAGEN is developing a fifth generation of QuantiFERON tests and exploring the use of artificial intelligence to identify individuals at risk of latent TB infection, thereby enhancing early risk prediction capabilities to support more targeted preventive treatment.
- Response to Market Demand: With approximately 10 million people developing active TB each year globally, QIAGEN is committed to meeting the increasing demand for TB testing by enhancing laboratory workflows and automation solutions, further solidifying its market leadership.
See More
Key Wall Street Ratings Updates on Friday
- Nvidia Price Target Raised: Daiwa increased Nvidia's price target from $205 to $215, anticipating that CEO Jensen Huang will showcase multiple AI success stories at the upcoming GTC Conference, which could positively impact the company's future performance.
- Qiagen Upgrade to Buy: Deutsche Bank upgraded Qiagen from hold to buy, noting that despite a nearly 30% drop in shares since January, the current price reflects the removal of any acquisition premium, suggesting potential for future price recovery.
- Nio Earnings Visibility: HSBC upgraded Nio from hold to buy, highlighting that new models and growth in its core portfolio may support volume growth and margin expansion, thereby enhancing its competitive position in the EV market.
- Linde Pricing Power: JPMorgan upgraded Linde from neutral to overweight, asserting that the chemical company possesses strong pricing power under current market conditions, which could help it maintain a competitive edge in the industry.
See More
Wall Street Analysts Adjust NIO Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on NIO stock, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Overview of Rating Updates: The adjustments include upgrades, downgrades, and initiations, indicating differing expectations from analysts regarding NIO's future performance, which may lead to stock price volatility.
- Market Reaction Potential: Changes in analyst ratings could attract investor attention, potentially impacting NIO's market performance, especially in the currently competitive electric vehicle sector.
- Investor Decision Impact: As analysts revise their views on NIO, investors may reassess their investment strategies, thereby affecting NIO's stock price trajectory and overall market confidence.
See More
